The pro‐fibrotic role of dipeptidyl peptidase 4 in carbon tetrachloride‐induced experimental liver injury

2016 ◽  
Vol 95 (5) ◽  
pp. 443-453 ◽  
Author(s):  
Xin M Wang ◽  
Lauren E Holz ◽  
Sumaiya Chowdhury ◽  
Shaun P Cordoba ◽  
Kathryn A Evans ◽  
...  
Nutrients ◽  
2019 ◽  
Vol 11 (1) ◽  
pp. 87 ◽  
Author(s):  
Beata Jarmołowska ◽  
Marta Bukało ◽  
Ewa Fiedorowicz ◽  
Anna Cieślińska ◽  
Natalia Karolina Kordulewska ◽  
...  

Opioid peptides released during digestion of dietary proteins such as casein, were suggested to contribute to autism development, leading to the announcement of opioid excess hypothesis of autism. This paper examines role of enzyme proline dipeptidyl peptidase-4 (DPPIV; EC 3.4.14.5) and it is exogenous substrate, β-casomorphin-7 (BCM7) in autism etiology. Our study included measurements of DPPIV and BCM7 concentrations in serum and urine, which were analyzed with ELISA assays and activity of DPPIV was measured by colorimetric test. The effect of opioid peptides from hydrolysed bovine milk on DPPIV gene expression in peripheral blood mononuclear cells (PBMC) in autistic and healthy children was determined using the Real-Time PCR (Polymerase Chain Reaction) method. Our research included 51 healthy children and 86 children diagnosed with autism spectrum disorder (ASD, ICDF84). We determined that the concentration of BCM7 in serum was significantly, 1.6-fold, higher in the ASD group than in controls (p < 0.0001). Concentration of DPPIV was found to also be significantly higher in serum from ASD children compared to the control group (p < 0.01), while we did not notice significant difference in enzymatic activity of serum DPPIV between the two study groups. We confirmed correlation according to the gender between analyzed parameters. The inspiration for this study emanated from clinical experience of the daily diet role in relieving the symptoms of autism. Despite this, we have concluded that milk-derived opioid peptides and DPPIV are potentially factors in determining the pathogenesis of autism; conducted studies are still limited and require further research.


2012 ◽  
Vol 287 (18) ◽  
pp. 14851-14862 ◽  
Author(s):  
Yaqin Zhang ◽  
Linping Wu ◽  
Yang Wang ◽  
Mingcao Zhang ◽  
Limin Li ◽  
...  

2009 ◽  
Vol 39 (2) ◽  
pp. 200-206 ◽  
Author(s):  
Chun-Ping Cui ◽  
Ping Wei ◽  
Yang Liu ◽  
Da-Jin Zhang ◽  
Li-Sheng Wang ◽  
...  

BMJ ◽  
2012 ◽  
Vol 344 (mar12 1) ◽  
pp. e1213-e1213 ◽  
Author(s):  
D. Lasserson ◽  
J. Mant

2017 ◽  
Vol 126 (05) ◽  
pp. 268-276 ◽  
Author(s):  
Fernando Gómez-Peralta ◽  
Cristina Abreu ◽  
Gustavo Mora-Navarro ◽  
Pilar López-Morandeira ◽  
Esteban Pérez-Gutierrez ◽  
...  

Abstract Introduction This study aimed to confirm the usefulness of basal insulin analogue plus oral antidiabetic drugs (OADs) for type 2 diabetes (T2D) patients inadequately controlled with premixed insulin with/without OADs and assess the role of dipeptidyl peptidase-4 (DPP-4) inhibitors within this regimen in clinical practice. Methods Spanish retrospective observational study that included 186 T2D patients with glycosylated hemoglobin (HbA1c) >7% (53 mmol/mol) despite premixed insulin with/without OADs who had been switched to basal insulin analogue plus OADs. Study data describing the situation before the treatment switch and 6 months later was retrospectively retrieved from patients’ medical charts. Results Switching to a basal insulin plus OADs decreased HbA1c (−1.0%, p<0.001), fasting (−38.1 mg/dl, p<0.001) and postprandial glycemia (−36.1 mg/dl, p<0.001), with reduced body weight (−1.1 kg, p<0.001) and hypoglycemic episodes (−17.5%, p<0.001). 68 (36.6%) patients received a basal insulin plus DPP-4 inhibitor±metformin and 74 (39.8%) plus metformin only. The DPP-4 inhibitor±metformin group showed a greater HbA1c reduction than the metformin group (1.3±1.4% vs. 0.9±1.0%, p=0.022), with no significant differences between groups in hypoglycemic episodes. Conclusions Basal insulin analogue plus OADs may be a useful treatment for type 2 diabetes patients inadequately controlled with premixed insulin. Administering DPP-4 inhibitors within this regimen may contribute to improve patients’ glycemia, with a favorable weight-change profile and without increasing hypoglycemia risk.


Sign in / Sign up

Export Citation Format

Share Document